Biodegradable Porous Microneedles for an Electric Skin Patch

Abe, Hiroya; Matsui, Yuuya; Kimura, Naruhiro; Nishizawa, Masatoyo

doi:10.1002/mame.202170033

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 33a,b,34 ] However, the MNs produced through these methods often suffer from structural collapse and low porosity issues. [ 34a,35 ] Moreover, both the MNs and their supporting substrate contain pores, which poses a potential risk of drug wastage, as only the drugs loaded in the MN part can be effectively delivered into the skin. In this study, we present a novel fabrication strategy for the PMN patch.…”

Section: Discussionmentioning

confidence: 99%

Self‐Healing Porous Microneedles Fabricated Via Cryogenic Micromoulding and Phase Separation for Efficient Loading and Sustained Delivery of Diverse Therapeutics

Ling,

Zheng,

et al. 2023

Small

View full text Add to dashboard Cite

Sustained‐release drug delivery formulations are preferable for treating various diseases as they enhance and prolong efficacy, minimize adverse effects, and avoid frequent dosing. However, these formulations are associated with poor patient compliance, require trained personnel for administration, and involve harsh manufacturing conditions that compromise drug stability. Here, a self‐healing biodegradable porous microneedle (PMN) patch is reported for sustained drug delivery. The PMN patch is fabricated by a cryogenic micromoulding followed by phase separation, leading to formation of interconnected pores on the surface and internals of MNs. The pores with self‐healing feature enable the PMNs to load hydrophilic drugs with different molecular weights in a mild and efficient manner. The healed PMNs can easily penetrate into the skin under press and detach from the supporting substrate under shear, thereby acting as implantable drug reservoirs for achieving sustained release of drugs for at least 40 days. One‐time administration of desired therapeutics using the sustained‐release healed PMNs resulted in stronger and longer‐lasting efficacy in mitigating psoriasis and eliciting immunity compared to conventional methods with multiple administrations. The self‐healing PMN patch for self‐administrated and long‐acting drug delivery can eventually improve medication adherence in prophylactic and therapeutic protocols that typically require frequent dosages.

show abstract

Section: Discussionmentioning

confidence: 99%

Self‐Healing Porous Microneedles Fabricated Via Cryogenic Micromoulding and Phase Separation for Efficient Loading and Sustained Delivery of Diverse Therapeutics

Ling,

Zheng,

et al. 2023

Small

View full text Add to dashboard Cite

show abstract

“…[ 12–14 ] Drug release kinetics from microneedle arrays is determined by a variety of factors, including microneedle architecture, the material used to prepare the microneedle arrays, the method by which the drug/bioactive is incorporated in/on the microneedle array. [ 13,15–17 ] Microneedle arrays that respond to stimuli (e.g., electricity, [ 8,18,19 ] light, [ 20 ] sound, [ 21,22 ] others, and potentially combinations thereof) [ 23–25 ] are an emerging class of arrays with exciting prospects for theranostic applications, [ 26–32 ] and inclusion in wearable devices useful for a variety of healthcare applications, [ 33 ] that have long term prospects for clinical impact, [ 34,35 ] particularly for the treatment of conditions where the use of needles is problematic (e.g., diabetes management). [ 36 , 37 ]…”

Section: Introductionmentioning

confidence: 99%

“…which facilitates their application in drug delivery, tissue engineering, etc. [ 19,44–48 ] Of particular interest for microneedle‐based technologies is their relatively low cost and ease of disposal as medical waste in accordance with a country's legal regulations (e.g., incineration, sterilization, etc.). [ 5 ] Metformin is a drug that is used in the treatment of diabetes [ 49–52 ] and cancer, [ 53–56 ] with emerging evidence of its potential for application in treating COVID‐19 [ 57,58 ] and aging‐related conditions.…”

Section: Introductionmentioning

confidence: 99%

Poly(2‐Hydroxyethyl Methacrylate) Hydrogel‐Based Microneedles for Metformin Release

Sharma,

Kap,

Abdelmohsen

et al. 2023

Global Challenges

View full text Add to dashboard Cite

The release of metformin, a drug used in the treatment of cancer and diabetes, from poly(2‐hydroxyethyl methacrylate), pHEMA, hydrogel‐based microneedle patches is demonstrated in vitro. Tuning the composition of the pHEMA hydrogels enables preparation of robust microneedle patches with mechanical properties such that they would penetrate skin (insertion force of a single microneedle to be ≈40 N). Swelling experiments conducted at 20, 35, and 60 °C show temperature‐dependent degrees of swelling and diffusion kinetics. Drug release from the pHEMA hydrogel‐based microneedles is fitted to various models (e.g., zero order, first order, second order). Such pHEMA microneedles have potential application for transdermal delivery of metformin for the treatment of aging, cancer, diabetes, etc.

show abstract

Morphology design of polymer microneedle arrays: Key factors from the application perspective

Jia,

Xia,

Wang

et al. 2023

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Biodegradable Porous Microneedles for an Electric Skin Patch

Cited by 4 publications

References 0 publications

Self‐Healing Porous Microneedles Fabricated Via Cryogenic Micromoulding and Phase Separation for Efficient Loading and Sustained Delivery of Diverse Therapeutics

Self‐Healing Porous Microneedles Fabricated Via Cryogenic Micromoulding and Phase Separation for Efficient Loading and Sustained Delivery of Diverse Therapeutics

Poly(2‐Hydroxyethyl Methacrylate) Hydrogel‐Based Microneedles for Metformin Release

Morphology design of polymer microneedle arrays: Key factors from the application perspective

Contact Info

Product

Resources

About